EpilepsyGTx, a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy, and ClearPoint Neuro (“ClearPoint”), a global therapy-enabling company offering precise navigation and delivery to the brain, today announced a partnership to support the targeted delivery of EpilepsyGTx’s lead gene therapy candidate, EPY201, for focal refractory epilepsy (FRE).
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2026 Diabetes Prevention Awareness Center.